Ligand Pharmaceuticals Incorporated (LGND)

Market Cap	2.25B
Revenue (ttm)	152.42M
Net Income (ttm)	45.24M
Shares Out	18.90M
EPS (ttm)	2.47
PE Ratio	48.22
Forward PE	33.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,758
Open	116.22
Previous Close	116.55
Day's Range	116.22 - 120.00
52-Week Range	57.00 - 129.90
Beta	0.90
Analysts	Strong Buy
Price Target	144.83 (+21.51%)
Earnings Date	Nov 7, 2024

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 18, 1992
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: LGND
• Website: https://www.ligand.com

Analyst Forecast

According to 6 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price forecast is $144.83, which is an increase of 21.51% from the latest price.

Price Target

$144.83

(21.51% upside)

Analyst Consensus: Strong Buy